Register for OBR daily

To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

APRI $2.69 2.3570 +718.60%
MACK $5.54 0.4200 +8.20%
VRML $1.11 0.0700 +6.73%
TGTX $6.41 0.3500 +5.78%
ARQL $1.50 0.0800 +5.63%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NWBO $0.47 -0.0706 -13.11%
GALE $0.28 -0.0261 -8.45%
FATE $2.39 -0.1150 -4.60%
ZIOP $5.55 -0.2500 -4.31%
ARIA $10.38 -0.4000 -3.71%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | Next > | Last >>

Data Presented at ESMO 2016 Adds to Understanding of Abraxane® as a Therapy for Patients with Historically Challenging Solid Tumors

(StreetInsider) Oct 7, 2016 - Multiple presentations evaluate ABRAXANE alone or in combination with novel agents and novel regimens to treat mPAC, NSCLC, and MBC.
read article 

Seattle Genetics and Agensys, an Affiliate of Astellas, Highlight Promising Enfortumab Vedotin (ASG-22ME) and ASG-15ME Phase 1 Data in Metastatic Urothelial Cancer at 2016 ESMO Congress

(Yahoo! Finance) Oct 7, 2016 - Seattle Genetics, Inc. and Agensys, an affiliate of Astellas, today presented updated clinical data for enfortumab vedotin (ASG-22ME) and ASG-15ME at the European Society for Medical Oncology (ESMO) Congress being held October 7-11, 2016 in Copenhagen, Denmark.
read article 

Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab in Advanced Genitourinary Tumors

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced results from a phase 1 trial of cabozantinib in combination with nivolumab in patients with previously treated genitourinary tumors.
read article 

Exelixis Announces Genentech Presentation of Preliminary Phase 1b Results for the Combination of Cobimetinib, Vemurafenib and Atezolizumab at ESMO 2016 Congress

(Yahoo! Finance) Oct 7, 2016 - Exelixis, Inc. today announced that its collaborator Genentech, a member of the Roche Group, will present preliminary results from a phase 1b clinical trial evaluating the safety and clinical activity of the triple combination of cobimetinib, vemurafenib, and atezolizumab in patients with previously untreated BRAF V600 mutation-positive advanced melanoma.
read article 

Kite Pharma Presents 12-Month Follow-Up Data From ZUMA-1 Phase 1 at the European Society for Medical Oncology (ESMO) Annual Congress

(Yahoo! Finance) Oct 7, 2016 - Kite Pharma, Inc. today announced updated results from the Phase 1 portion of Kite's ZUMA-1 clinical trial of its lead product candidate, KTE-C19, in patients with chemorefractory, aggressive non-Hodgkin lymphoma (NHL). The results were provided in an oral presentation at the European Society for Medical Oncology (ESMO) annual congress.
read article 

Clovis Oncology Presents Efficacy and Safety Data From New Drug Application (NDA) Population for Rucaparib in the Treatment of Advanced Mutant BRCA Ovarian Cancer at 2016 ESMO Congress

(Clovis) Oct 7, 2016 - Clovis Oncology announced today the oral presentation of the primary efficacy and safety data from its NDA dataset for rucaparib at the 2016 ESMO Congress in Copenhagen.
read corporate press release 

Suboptimal Reporting of Adverse Events in Pivotal Cancer CTs

(Medscape Medical News) Oct 7, 2016 - During the past 15 years, most pivotal trials of new drugs that were approved by the US Food and Drug Administration (FDA) for treatment of solid malignancies in adults had suboptimal reporting of adverse events (AEs), according to researchers.
read article (free registration required) 

ESMO 2016 Press Release: High Response Rate In Phase I/II Paediatric Brain Cancer Trial Sets Stage for Combination Therapy With Higher Response and Lower Toxicity

(ESMO) Oct 7, 2016 - A high response rate with a single drug in a phase I/II trial of paediatric brain tumour has set the stage for combination therapy with higher response and lower toxicity, researchers reported at the ESMO 2016 Congress in Copenhagen.
read press release 

ESMO 2016 Press Release: Neoadjuvant Immunotherapy Prior to Surgery is Safe and Feasible in Early Lung Cancer

(ESMO) Oct 7, 2016 - Neoadjuvant immunotherapy with the PD-1 inhibitor nivolumab is safe and feasible prior to surgery for early lung cancer, researchers reported at the ESMO 2016 Congress in Copenhagen.
read press release 

Thousands of European Melanoma Patients Lack Access to New Drugs

(Reuters) Oct 7, 2016 - More than a quarter of European patients with advanced melanoma lack access to new treatments that could extend their lives, according to findings presented at a major cancer conference on Friday.
read article 

Clovis Falls on Fears Ovarian Cancer Drug Inferior to Competition

(TheStreet) Oct 7, 2016 - Clovis Oncology shares are falling Friday after a clinical trial update on its PARP inhibitor in ovarian cancer revealed weaknesses against a similar, competing drug from AstraZeneca.
read article 

Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership

(Teva) Oct 6, 2016 - Teva to commercialize proposed monoclonal antibody (mAb) biosimilars to Rituxan® (rituximab) and Herceptin® (trastuzumab) in the U.S. and Canada.
read corporate press release 

Alnylam Shuts Down Drug Development Program

(Boston Globe) Oct 5, 2016 - Alnylam Pharmaceuticals Inc. said Wednesday it is abandoning a late-stage clinical trial of an experimental drug to treat a rare life-threatening heart and nerve disease, the second development setback in the past week for the Cambridge company.
read article (free registration required) 

Theranos Exits Lab Business

(Forbes) Oct 6, 2016 - Last night laboratory testing business Theranos announced that it would lay off 340 people, or 43% of its workforce, and get out of the business of administering blood tests–a business which has drawn the scrutiny of multiple government agencies and led the Centers for Medicare & Medicaid Services to try to ban Theranos founder and chief executive Elizabeth Holmes from the diagnostics industry.
read article 

UnitedHealth Accused of Gouging Customers on Prescription Drugs

(Bloomberg) Oct 6, 2016 - Some UnitedHealth Group Inc. customers claim the health insurer defrauded them by setting up a system that secretly overcharged for prescription drugs.
read article 

Your Surgeon Is Probably a Republican, Your Psychiatrist Probably a Democrat

(New York Times/The Upshot) Oct 6, 2016 - We know that Americans are increasingly sorting themselves by political affiliation into friendships, even into neighborhoods. Something similar seems to be happening with doctors and their various specialties.
read article 

New Virtual Reality Program For Young Cancer Patients Aims To Lift Their Spirit

(USC News) Oct 5, 2016 - The USC Norris Comprehensive Cancer Center has teamed with a nonprofit on a virtual reality initiative for patients in the Adolescent and Young Adult Cancer program at USC (AYA@USC).
read article 

A Cure for a Childhood Cancer—But Will It Last?

(MIT Technology Review) Oct 5, 2016 - Modifying a child’s immune system to fight off leukemia can yield dramatic results, but the treatments are dangerous and no-one knows if they’re permanent.
read article 

Charles S. Fuchs to Lead Yale Cancer Center and Smilow Cancer Hospital

(Yale News) Oct 6, 2016 - After an extensive national search, Smilow Cancer Hospital at Yale New Haven and Yale Cancer Center (YCC) have announced that Dr. Charles S. Fuchs will become the new YCC director and physician-in-chief at Smilow Cancer Hospital at Yale New Haven, effective Jan. 1, 2017.
read article 

MDxHealth Reports Highmark Blue Cross Blue Shield Issues Positive Medical Policy on ConfirmMDx

(Yahoo! Finance) Oct 6, 2016 - MDxHealth SA today announced that Highmark BCBS has issued a positive medical coverage policy decision for the ConfirmMDx® for Prostate Cancer test.
read article 

AMA Survey Asks Oncologists to Assess Relative Value of CPT Codes

(ASCO in Action) Oct 5, 2016 - In the next few weeks, the American Society of Clinical Oncology (ASCO) in collaboration with multiple specialty societies will randomly distribute an American Medical Association (AMA) Relative Value Scale Update Committee (RUC) survey of the following Current Procedural Terminology (CPT) Codes:
read article 

Primary Care Docs Participating in Breast Cancer Decisions

(Reuters Health) Oct 5, 2016 - Most women in a new U.S. survey said their primary care physician was involved in their breast cancer care during treatment, and rated their doctor’s engagement and communication levels as high.
read article 

U.S. Colon Cancer Care Improves When Insurance Access Expands

(Reuters Health) Oct 5, 2016 - Americans with colon and rectal cancers may get better care when states expand access to health insurance, a new study suggests.
read article 

Cellectar Biosciences Announces Enrollment of First Patient into Third Cohort of Its Phase I Clinical Study of CLR 131 in Multiple Myeloma

(NASDAQ) Oct 6, 2016 - Cellectar Biosciences, Inc., an oncology-focused clinical stage biotechnology company, today announces the enrollment of the first patient into Cohort 3 of the company's Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma.
read article 

Kite Pharma Initiates Phase 1b/2 Combination Study for KTE-C19 and Atezolizumab in Patients with Refractory Diffuse Large B-cell Lymphoma (DLBCL)

(Yahoo Finance!) Oct 6, 2016 - Kite Pharma, Inc. today announced the first patient was enrolled in ZUMA-6, a Phase 1b/2 clinical study of KTE-C19 in combination with atezolizumab, Genentech’s anti-PD-L1 cancer immunotherapy. The trial is designed to evaluate the safety and efficacy of the combination in patients with refractory diffuse large B-cell lymphoma (DLBCL).
read article